CoChat

Inhibition of Histone Deacetylases in Inflammatory Bowel Diseases

Open access
Glauben, Rainer, Siegmund, Britta · 2011 · Molecular Medicine
Cited by 77

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

This review, comprised of our own data and that of others, provides a summary overview of histone deacetylase (HDAC) inhibition on intestinal inflammation as well as inflammation-mediated carcinogenesis. Experimental colitis in mice represents an excellent in vivo model to define the specific cell populations and target tissues modulated by inhibitors of HDAC. Oral administration of either suberyolanilide hydroxamic acid (SAHA) or ITF2357 results in an amelioration in these models, as indicated by a significantly reduced colitis disease score and histological score. This effect was paralleled by suppression of proinflammatory cytokines at the site of inflammation as well as specific changes in the composition of cells within the lamina propria. In addition, tumor number and size was significantly reduced in two models of inflammation-driven tumorigenesis, namely interleukin (IL)-10-deficient mice and the azoxymethane-dextran sulfate sodium (DSS) model, respectively. The mechanisms affected by HDAC inhibition, contributing to this antiinflammatory and antiproliferative potency will be discussed in detail. Furthermore, with regard to the relevance in human inflammatory bowel disease, the doses of ITF2357 considered safe in humans and the corresponding serum concentrations are consistent with the efficacious dosing used in our in vivo as well as in vitro experiments. Thus, the data strongly suggest that HDAC inhibitors could serve as a therapeutic option in inflammatory bowel disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2119/molmed.2011.00069

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 73

  1. Mathew CG. (2008) New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat. Rev. Genet. 9:9–14. · DOI · Paper page
  2. Baumgart DC, Carding SR. (2007) Inflammatory bowel disease: cause and immunobiology. Lancet. 369:1627–40. · DOI · Paper page
  3. Soderlund S, et al. (2009). Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 136:1561–67. · DOI · Paper page
  4. Karin M, Greten FR. (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5:749–59. · DOI · Paper page
  5. Tarmin L, et al. (1995) Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res. 55:2035–8.
  6. Furlan A, et al. (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17:353–362. · DOI
  7. Norris KL, Lee JY, Yao TP. (2009) Acetylation goes global: the emergence of acetylation biology. Sci. Signal. 2:pe76. · DOI · Paper page
  8. Spange S, Wagner T, Heinzel T, Kramer OH. (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 41:185–98. · DOI · Paper page
  9. Fuss IJ, et al. (2004) Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113:1490–7. · DOI · Paper page
  10. Fuss IJ, et al. (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157:1261–70. · DOI · Paper page
  11. Stuber E, Strober W, Neurath M. (1996) Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J. Exp. Med. 183:693–8. · DOI · Paper page
  12. Zhang X, et al. (2011) Interleukin-1 receptor signaling is required to overcome the effects of pertussis toxin and for efficient infection- or vaccination-induced immunity against Bordetella pertussis. Infect. Immun. 79:527–41. · DOI
  13. Zhou L, et al. (2007) IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8:967–74. · DOI · Paper page
  14. Fuss IJ, et al. (2006) Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12:9–15. · DOI · Paper page
  15. Umetsu DT, DeKruyff RH. (1997) Th1 and Th2 CD4+ cells in the pathogenesis of allergic diseases. Proc. Soc. Exp. Biol. Med. 215:11–20. · doi:10.3181/00379727-215-44109
  16. Bouma G, Strober W. (2003) The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3:521–33. · DOI · Paper page
  17. Heller F, et al. (2005) Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 129:550–64. · DOI · Paper page
  18. Stephens GL, Shevach EM. (2007) Foxp3+ regulatory T cells: selfishness under scrutiny. Immunity. 27:417–9. · doi:10.1016/j.immuni.2007.08.008
  19. Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8:457–62. · DOI · Paper page
  20. Ruemmele FM, Brousse N, Goulet O. (2004) Autoimmune enteropathy: molecular concepts. Curr. Opin. Gastroenterol. 20:587–91. · doi:10.1097/00001574-200411000-00014
  21. Ochs HD, Gambineri E, Torgerson TR. (2007) IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol. Res. 38:112–21. · DOI · Paper page
  22. McDonel P, Costello I, Hendrich B. (2009) Keeping things quiet: roles of NuRD and Sin3 co-repressor complexes during mammalian development. Int. J. Biochem. Cell Biol. 41:108–16. · DOI · Paper page
  23. Feng Q, Zhang Y. (2001) The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 15:827–832.
  24. Chang S, Collins PL, Aune TM. (2008) T-bet dependent removal of Sin3A-histone deacetylase complexes at the Ifng locus drives Th1 differentiation. J. Immunol. 181:8372–81. · DOI
  25. Chen GY, Osada H, Santamaria-Babi LF, Kannagi R (2006) Interaction of GATA-3/T-bet transcription factors regulates expression of sialyl Lewis X homing receptors on Th1/Th2 lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 103:16894–9. · DOI
  26. Sarra M, Pallone F, Macdonald TT, Monteleone G. (2010) IL-23/IL-17 axis in IBD. Inflamm. Bowel Dis. 16:1808–13. · DOI · Paper page
  27. Edens RE, Dagtas S, Gilbert KM. (2006) Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int. Immunopharmacol. 6:1673–81. · DOI
  28. Moreira JM, Scheipers P, Sorensen P. (2003) The histone deacetylase inhibitor trichostatin A modulates CD4+ T cell responses. BMC Cancer. 3:30. · DOI
  29. Matsuoka H, Fujimura T, Mori H, Aramori I, Mutoh S. (2007) Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. Int. Immunopharmacol. 7:1422–32. · DOI
  30. Koenen HJ, et al. (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 112:2340–52. · DOI · Paper page
  31. Wang L, de Zoeten EF, Greene MI, Hancock WW. (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat. Rev. Drug. Discov. 8:969–81. · DOI · Paper page
  32. Tao R, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13:1299–307. · DOI · Paper page
  33. Wang L, Tao R, Hancock WW. (2009) Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance. Immunol. Cell Biol. 87:195–202. · DOI
  34. de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 138:583–94. · DOI · Paper page
  35. Bosisio D, et al. (2008) Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J. Leukoc. Biol. 84:1540–8. · DOI
  36. Jung ID, et al. (2009) Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-derived dendritic cells. Int. J. Immunopathol. Pharmacol. 22:501–15. · DOI
  37. Brogdon JL, et al. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 109:1123–30. · DOI · Paper page
  38. Sun Y, et al. (2009) Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J. Immunol. 182:5899–903. · DOI · Paper page
  39. Reddy P, et al. (2008) Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118:2562–73.
  40. Aung HT, et al. (2006) LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J. 20:1315–27. · DOI · Paper page
  41. Deng WG, Zhu Y, Wu KK. (2004) Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood. 103:2135–42. · DOI · Paper page
  42. Maa MC, et al. (2010) Butyrate reduced lipopolysaccharide-mediated macrophage migration by suppression of Src enhancement and focal adhesion kinase activity. J. Nutr. Biochem. 21:1186–92. · DOI
  43. Grabiec AM, et al. (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 184:2718–28. · DOI · Paper page
  44. Choi Y, et al. (2008) Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model. Exp. Mol. Med. 40:574–81. · DOI
  45. Lal G, et al. (2009) Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol. 182:259–273. · DOI · Paper page
  46. Polansky JK, et al. (2008) DNA methylation controls Foxp3 gene expression. Eur. J. Immunol. 38:1654–63. · DOI · Paper page
  47. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. (2006) Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 66:1277–81. · DOI · Paper page
  48. Schickel R, Boyerinas B, Park SM, Peter ME (2008) MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 27:5959–74. · DOI · Paper page
  49. Baltimore D, Boldin MP, O’Connell RM, Rao DS, Taganov KD. (2008) MicroRNAs: new regulators of immune cell development and function. Nat. Immunol. 9:839–45. · DOI · Paper page
  50. Faraco G, et al. (2009) Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol. Dis. 36:269–79. · DOI · Paper page
  51. Kiernan R, et al. (2003) Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 278:2758–66. · DOI · Paper page
  52. Shibata W, et al. (2007) Cutting edge: the IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J. Immunol. 179:2681–5. · DOI · Paper page
  53. Nenci A, et al. (2007) Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446:557–61. · DOI · Paper page
  54. Chen L, Fischle W, Verdin E, Greene WC. (2001) Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 293:1653–7. · DOI · Paper page
  55. Ashburner BP, Westerheide SD, Baldwin AS Jr. (2001) The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21:7065–77. · DOI · Paper page
  56. Imre G, Gekeler V, Leja A, Beckers T, Boehm M. (2006) Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation. Cancer Res. 66:5409–18. · DOI · Paper page
  57. Liu H, et al. (2006) Trichostatin A regulates hGCN5 expression and cell cycle on daudi cells in vitro. J. Huazhong Univ. Sci. Technolog. Med. Sci. 26:534–7. · DOI
  58. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. (2006) Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J. Biol. Chem. 281:5612–22. · DOI · Paper page
  59. Glauben R, et al. (2008) Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut. 57:613–622. · DOI
  60. Kramer OH, et al. (2006) Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev. 20:473–485. · DOI · Paper page
  61. Glauben R, et al. (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176:5015–22. · DOI · Paper page
  62. Marks PA, Dokmanovic M. (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs. 14:1497–511. · DOI · Paper page
  63. Reilly CM, et al. (2008) The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J. Autoimmun. 31:123–30. · DOI
  64. Saouaf SJ, et al. (2009) Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 87:99–104. · doi:10.1016/j.yexmp.2009.06.003
  65. Leoni F, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11:1–15. · DOI · Paper page
  66. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. (1995) Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182:1281–90. · DOI · Paper page
  67. Boirivant M, Fuss IJ, Chu A, Strober W. (1998) Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188:1929–39. · DOI · Paper page
  68. Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452–8. · DOI · Paper page
  69. Neurath MF, et al. (2001) Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol. 22:21–6. · DOI · Paper page
  70. Lugering A, et al. (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology. 121:1145–57. · DOI · Paper page
  71. Tanaka T, et al. (2003) A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 94:965–73. · DOI · Paper page
  72. Hegazi RA, et al. (2003) Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflamm. Bowel Dis. 9:230–36. · DOI
  73. Chateauvieux S, Morceau F, Dicato M, Diederich M. (2010) Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. 2010:479364. · DOI · Paper page

Cited by

See all 77

Metadata

Authors
Glauben, R., & Siegmund, B.
Venue
Molecular Medicine
Published
2011-02-22
Volume
17
Issue
5-6
Pages
426-433
ISSN
  • 1076-1551 (ISSN-L)
  • 1528-3658
OpenAlex
W2307241
Cited by
77
References
8
FWCI
3.29
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.